Establishment Labs (ESTA) Projected to Post Earnings on Wednesday

Establishment Labs (NASDAQ:ESTA) is expected to announce its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect the company to announce earnings of ($0.3556) per share and revenue of $57.4710 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 8:30 AM ET.

Establishment Labs (NASDAQ:ESTA) last posted its earnings results on Tuesday, February 24th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.13. Establishment Labs had a negative return on equity of 201.79% and a negative net margin of 24.19%.The business had revenue of $64.62 million during the quarter, compared to analyst estimates of $63.80 million. During the same quarter last year, the company earned ($1.19) EPS. The company’s quarterly revenue was up 45.2% compared to the same quarter last year. On average, analysts expect Establishment Labs to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Establishment Labs Stock Down 1.6%

ESTA stock opened at $64.40 on Wednesday. The stock has a market capitalization of $1.89 billion, a P/E ratio of -37.01 and a beta of 1.08. The company has a debt-to-equity ratio of 10.51, a current ratio of 3.04 and a quick ratio of 2.00. Establishment Labs has a 1-year low of $28.89 and a 1-year high of $83.31. The business has a fifty day moving average price of $65.95 and a 200-day moving average price of $65.71.

Analysts Set New Price Targets

ESTA has been the subject of several research analyst reports. Mizuho lifted their price objective on Establishment Labs from $90.00 to $100.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Establishment Labs in a report on Friday, March 27th. Canaccord Genuity Group lifted their price target on shares of Establishment Labs from $85.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Wall Street Zen cut shares of Establishment Labs from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Finally, Citigroup lowered their price objective on shares of Establishment Labs from $81.00 to $74.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 11th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $86.86.

Insider Activity at Establishment Labs

In related news, Director Quiros Juan Jose Chacon sold 2,180 shares of the company’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $66.26, for a total transaction of $144,446.80. Following the completion of the sale, the director owned 1,107,504 shares in the company, valued at approximately $73,383,215.04. This represents a 0.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 150,000 shares of company stock valued at $9,629,263 over the last three months. Insiders own 9.99% of the company’s stock.

Institutional Investors Weigh In On Establishment Labs

Large investors have recently made changes to their positions in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Establishment Labs by 20.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 57,215 shares of the company’s stock valued at $2,335,000 after purchasing an additional 9,557 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Establishment Labs by 1.2% in the second quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock worth $1,105,000 after buying an additional 299 shares during the last quarter. WINTON GROUP Ltd bought a new stake in Establishment Labs during the second quarter valued at approximately $651,000. Nebula Research & Development LLC grew its position in Establishment Labs by 27.9% during the second quarter. Nebula Research & Development LLC now owns 16,214 shares of the company’s stock valued at $692,000 after buying an additional 3,538 shares during the period. Finally, Sei Investments Co. increased its holdings in Establishment Labs by 13.3% during the second quarter. Sei Investments Co. now owns 48,428 shares of the company’s stock valued at $2,068,000 after buying an additional 5,668 shares during the last quarter. 72.91% of the stock is currently owned by institutional investors.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.